Collegium Pharmaceutical (NASDAQ:COLL) Upgraded at Needham & Company LLC

Needham & Company LLC upgraded shares of Collegium Pharmaceutical (NASDAQ:COLLFree Report) from a hold rating to a buy rating in a research note issued to investors on Friday, Marketbeat.com reports. The firm currently has $46.00 price target on the specialty pharmaceutical company’s stock.

Other analysts also recently issued reports about the company. Piper Sandler reiterated a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $43.80.

Check Out Our Latest Stock Analysis on Collegium Pharmaceutical

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $32.91 on Friday. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of 14.19 and a beta of 0.82. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The business’s 50 day simple moving average is $30.56 and its 200-day simple moving average is $34.07. Collegium Pharmaceutical has a 12 month low of $28.39 and a 12 month high of $42.29.

Institutional Trading of Collegium Pharmaceutical

Institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC raised its stake in Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 792 shares during the last quarter. CWM LLC grew its holdings in shares of Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after buying an additional 736 shares in the last quarter. TD Private Client Wealth LLC raised its position in shares of Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after buying an additional 483 shares during the last quarter. Virtus Fund Advisers LLC purchased a new position in shares of Collegium Pharmaceutical during the third quarter valued at approximately $72,000. Finally, AXA S.A. acquired a new stake in Collegium Pharmaceutical during the second quarter worth approximately $209,000.

About Collegium Pharmaceutical

(Get Free Report)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Recommended Stories

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.